The Predictive Effect of Overexpressed MiR-34a on Good Survival of Cancer Patients: a Systematic Review and Meta-analysis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2015 Oct 8

PMID 26445554

Citations 10

Authors

Jian Wang

Guorong Dan

Jiqing Zhao

Yu Ding

Feng Ye

Huiqin Sun

Fan Jiang

Jin Cheng

Fahuan Yuan

Zhongmin Zou

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNA-34a (miR-34a) is a potential prognostic factor for survival in patients with several types of cancer according to previous clinical researches. We conducted a systematic review and meta-analysis to summarize the significance of increased miR-34a expression in the prognosis of patients' overall survival.

Materials And Methods: The present systematic review and meta-analysis of 15 researches included 2,597 patients. Overexpression of miR-34a may predict good overall survival ([OS], HR =0.76, 95% confidence interval: 0.55-1.06, P=0.105), but the effect was not significant enough. Subgroup analysis results showed miR-34a was an ideal predictor for digestive system cancer (OS, HR =0.50, 95% confidence interval: 0.25-0.99, P=0.048). The predictive effects of elevated expression of miR-34a on the OS of untreated and treated patients were not of obvious differences.

Conclusion: This systematic review and meta-analysis showed that miR-34a has a predictive effect on overall survival of patients with digestive system cancer.

Citing Articles

HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma.

Badami E, Carcione C, Chinnici C, Tinnirello R, Conaldi P, Iannolo G Front Oncol. 2022; 11:803278.

PMID: 35127513 PMC: 8812294. DOI: 10.3389/fonc.2021.803278.

MicroRNA-34a in coronary heart disease: Correlation with disease risk, blood lipid, stenosis degree, inflammatory cytokines, and cell adhesion molecules.

Li H, Chen M, Feng Q, Zhu L, Bai Z, Wang B J Clin Lab Anal. 2021; 36(1):e24138.

PMID: 34861059 PMC: 8761464. DOI: 10.1002/jcla.24138.

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H Br J Cancer. 2020; 122(11):1630-1637.

PMID: 32238921 PMC: 7251107. DOI: 10.1038/s41416-020-0802-1.

Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics.

Yang F, Li H, Li T, Zhao Y, Liu Z, Li X Biomed Res Int. 2019; 2019:2063823.

PMID: 31061821 PMC: 6466945. DOI: 10.1155/2019/2063823.

lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway.

Li Y, Li C, Li D, Yang L, Jin J, Zhang B Onco Targets Ther. 2019; 12:2649-2660.

PMID: 31040703 PMC: 6462170. DOI: 10.2147/OTT.S188054.

References

Gallardo E, Navarro A, Vinolas N, Marrades R, Diaz T, Gel B . miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009; 30(11):1903-9. DOI: 10.1093/carcin/bgp219. View

Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T . Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 2012; 132(12):2884-93. DOI: 10.1002/ijc.27981. View

Huang D, Wang H, Liu R, Li H, Ge S, Bai M . miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem. 2013; 115(3):549-56. DOI: 10.1002/jcb.24689. View

Guo H, Ingolia N, Weissman J, Bartel D . Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-40. PMC: 2990499. DOI: 10.1038/nature09267. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Zenz T, Mohr J, Eldering E, Kater A, Buhler A, Kienle D . miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2008; 113(16):3801-8. DOI: 10.1182/blood-2008-08-172254. View

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

Genovese G, Ergun A, Shukla S, Campos B, Hanna J, Ghosh P . microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov. 2012; 2(8):736-49. PMC: 3911772. DOI: 10.1158/2159-8290.CD-12-0111. View

Gao H, Zhao H, Xiang W . Expression level of human miR-34a correlates with glioma grade and prognosis. J Neurooncol. 2013; 113(2):221-8. DOI: 10.1007/s11060-013-1119-1. View

10.

Ogawa T, Saiki Y, Shiga K, Chen N, Fukushige S, Sunamura M . miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. Cancer Sci. 2012; 103(9):1737-43. PMC: 7659179. DOI: 10.1111/j.1349-7006.2012.02338.x. View

11.

Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M . Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene. 2011; 30(38):4038-49. DOI: 10.1038/onc.2011.119. View

12.

Chang T, Wentzel E, Kent O, Ramachandran K, Mullendore M, Lee K . Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26(5):745-52. PMC: 1939978. DOI: 10.1016/j.molcel.2007.05.010. View

13.

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View

14.

Jamieson N, Morran D, Morton J, Ali A, Dickson E, Carter C . MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011; 18(2):534-45. DOI: 10.1158/1078-0432.CCR-11-0679. View

15.

Navarro A, Clot G, Prieto M, Royo C, Vegliante M, Amador V . microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clin Cancer Res. 2013; 19(12):3121-9. PMC: 3691513. DOI: 10.1158/1078-0432.CCR-12-3077. View

16.

Bader A . miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012; 3:120. PMC: 3387671. DOI: 10.3389/fgene.2012.00120. View

17.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

18.

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

19.

Welch C, Chen Y, Stallings R . MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007; 26(34):5017-22. DOI: 10.1038/sj.onc.1210293. View

20.

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N . Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 26(5):731-43. DOI: 10.1016/j.molcel.2007.05.017. View